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Abstract
Background: Uncovering the molecular mechanisms involved in epileptogenesis is critical to better understand
the physiopathology of epilepsies and to help develop new therapeutic strategies for this prevalent and severe
neurological condition that affects millions of people worldwide.
Results: Changes in the transcriptome of hippocampal cells from rats subjected to the pilocarpine model of
epilepsy were evaluated by microarrays covering 34,000 transcripts representing all annotated rat genes to date.
Using such genome-wide approach, differential expression of nearly 1,400 genes was detected during the course
of epileptogenesis, from the early events post status epilepticus (SE) to the onset of recurrent spontaneous seizures.
Most of these genes are novel and displayed an up-regulation after SE. Noteworthy, a group of 128 genes was
found consistently hyper-expressed throughout epileptogenesis, indicating stable modulation of the p38MAPK, Jak-
STAT, PI3K, and mTOR signaling pathways. In particular, up-regulation of genes from the TGF-beta and IGF-1
signaling pathways, with opposite effects on neurogenesis, correlate with the physiopathological changes reported
in humans.
Conclusions: A consistent regulation of genes functioning in intracellular signal transduction regulating
neurogenesis have been identified during epileptogenesis, some of which with parallel expression patterns
reported in patients with epilepsy, strengthening the link between these processes and development of epilepsy.
These findings reveal dynamic molecular changes occurring in the hippocampus that may serve as a starting point
for designing alternative therapeutic strategies to prevent the development of epilepsy after acquired brain insults.
Background
Chronic brain disorders have a profound impact on life
quality since most of them are associated with cognitive
impairment, and disturbance of personality or behavior.
With the tendency of global population aging, the inci-
dence of people living with such disabilities will drama-
tically increase in the next decades. Epilepsy is one
example of prevalent and severe neurological condition,
affecting approximately 50 million people worldwide [1].
Epidemiological studies reveal that about 20 to 30% of
patients with epilepsy are refractory to the currently
available therapies and continue to have seizures
throughout their lives [2]. Temporal lobe epilepsy
(TLE), which is characterized by atrophy of mesial tem-
poral structures and hippocampal sclerosis, is the most
frequent form of partial epilepsy and also the most com-
mon form of drug-refractory epilepsy [3].
The mechanisms of action of most clinically used
drugs in human established epilepsies are based upon
the synchronized neuronal activity and unbalance
between inhibitory and excitatory neurotransmission,
which are common features linked to the pathogenesis
of epilepsy [4]. In that sense, voltage-gated ion channels,
gabaergic, and glutamatergic systems are the classic
therapeutic targets. However, these drugs act to restrain
epileptic seizures in already established epilepsies rather
than preventing the development of epilepsy after
acquired brain insults.
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Uncovering the molecular mechanisms involved in
epileptogenesis is critical to understand the physio-
pathology of epilepsies and to help develop new thera-
peutic strategies based on drugs with anti-epileptogenic
activity. The identification of potential therapeutic tar-
gets, however, should be facilitated by the knowledge of
genes, proteins, and signaling pathways altered during
the different stages of epilepsy development.
In the post-genomic era, DNA microarrays are being
widely used as an experimental tool to monitor changes
in gene expression levels in different pathologies. In epi-
lepsy, the clinical implications of the microarray tech-
nology are illustrated in a few recent publications in the
literature [5-9]. One drawback of such approach in
humans, however, is that the experimental design is not
trivial due to the lack of appropriate control samples of
healthy brain tissue. Furthermore, surgical specimens
often available for study do not allow correlation with
the early stages of the disease. Alternatively, key molecu-
lar alterations during epileptogenesis can be examined in
animals subjected to classical models of experimental
epilepsy. Several well-characterized models have been
described in the last decades and in many ways they
mimic complex partial seizures observed in patients
with TLE [10].
Recent reports of gene expression profiling are avail-
able for some of these animal models [11-15], albeit
with partial transcriptome coverage and time points
more closely related with responses to either status epi-
lepticus (SE) or cumulative chronic spontaneous sei-
zures. A comprehensive gene expression profiling
designed for the study of epileptogenic process, from
the early molecular changes induced by hippocampal
injury to the onset of epilepsy, is still lacking.
In this work, we performed a genome wide analysis of
genes differentially expressed during epileptogenesis.
Virtually, all possible changes in the rat transcriptome
were monitored at distinct time points corresponding to
the latent to chronic phase transition of the pilocarpine
model of epilepsy, one the most extensively studied che-
mically induced model of TLE [16-18]. Genes identified
as being differentially expressed were classified based on
their respective biological functions to envisage pro-
cesses and pathways likely implicated in epileptogenesis.
Genes stably up-regulated and working in a concerted
fashion were identified, some of which displaying a par-
allel expression pattern in humans with epilepsy, sug-
gesting their possible value as targets for therapy.
Methods
Animal model
Male adult Wistar rats (200-250 g) were used through-
out the study. Animals were housed under standard
controlled conditions (7:00 AM/7:00 P.M. light/dark
cycle; 20-22°C; 45-55% humidity) with food and water
ad libitum. All efforts were made to minimize animal
suffering following the proposal of International Ethical
Guideline for Biomedical Research (CIOMS/OMS,
1985). The study was approved by the Ethics Committee
for animal research of the Federal University of São
Paulo, Brazil (CEP 2053/07).
Animals (n = 5 per experimental group) were sub-
jected to the pilocarpine model of epilepsy [19,20].
Briefly, rats were pre-treated with a subcutaneous injec-
tion of scopolamine methylnitrate (1 mg/kg, to minimize
peripheral cholinergic effects), followed by a single dose
of pilocarpine (350 mg/kg, dissolved in saline) (Sigma
Chemical, USA) injected intraperitoneally. Control ani-
mals received the same amount of saline only. After 4 h
of SE, pilocarpine-treated rats (Pilo) received diazepam
(8 mg/kg i.p.) to block behavioral and electrographic sei-
zures. Occurrence of spontaneous seizures was detected
by continued video monitoring of animals.
Microarray hybridization
Gene expression profiling was analyzed in hippocampi
of rats treated with pilocarpine at different times during
the course of epileptogenesis: 3 days post-SE (3 D), 7
days post-SE (7 D), and immediately (up to 12 h) after
the first spontaneous seizure (Chronic). All three pilo-
carpine subgroups had a corresponding age-matched
control group (saline-treated rats), from which normal
hippocampi samples were obtained at the same experi-
mental time points. Rats were killed by decapitation and
the hippocampi were removed at 4°C within a period no
longer than three minutes. Brain tissues were snap fro-
zen in liquid nitrogen and stored at -80°C until RNA
extraction with the RNeasy kit (Qiagen), following the
manufacturer’s protocol. Evaluation of RNA quantifica-
tion and purification was carried out by measuring
absorbance at 260 and 280 nm. A260/A280 ratios in the
range of 1.8-2.0 were considered satisfactory for purity
standards. Denaturing agarose gel electrophoresis was
used to assess the quality of RNA samples.
Independent microarray hybridizations were carried
out for each sample (n = 5, per experimental group)
with oligonucleotide microarrays covering 34,000 tran-
scripts representing all known and predictive genes of
the rat genome (CodeLink™ Rat Whole Genome Bioar-
rays, GE Healthcare), following the manufacturer’s pro-
tocol. Detailed descriptions of the Bioarray platform and
expression data are publicly available, according to
MIAME guidelines, at the GEO database under the
accession numbers GPL2896 and GSE14763. Briefly,
total RNA was extracted with RNeasy spin columns and
treated with RNAse free-DNAse (Qiagen). One micro-
gram of total RNA was reverse transcribed in the pre-
sence of T7- oligo dT primer. The resulting cDNA was
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used for in vitro transcription reaction using T7 RNA
polymerase and biotinylated dUTP. Ten micrograms of
target cRNA was fragmented at 94°C for 20 min and
hybridized to the bioarrays at 37°C for 18 h, under 300
rpm agitation. After staining with streptavidin-conju-
gated Cyanine-5 dye, the slides were washed and fluor-
escence was measured using an Axon GenePix 4000B
Scanner (Axon Instruments Inc).
Gene Expression measurement
The fluorescent images were captured using GenePix
Pro v.4.1 (Axon Instruments Inc) and the light intensi-
ties were quantified, corrected for background noise,
and normalized with the CodeLink™ Expression Analysis
v4.1. Spots with background contamination, shape irre-
gularity, or pixel saturation were filtered out. Only spots
flagged as “good” (G) or “low” (L) were considered in
the subsequent analysis. Since the CodeLink™ system is
a one-color platform, we grouped the meaningful com-
parisons in pairs to form ratios, as usual in two-color
co-hybridized microarray platforms. Differentially
expressed genes were identified by comparing the fluor-
escence values of a given spot (transcript) in samples
from pilocarpine-treated rats vs. pair-matched control
rats, using an intensity-dependent dynamic cutoff with
99% credibility level. Genes displaying expression
changes equal or higher than two fold (P ≤ 0.05) were
included in the analysis. These differentially expressed
genes were grouped by unsupervised hierarchical clus-
tering using correlation and average linkage metrics as
described elsewhere [21].
Gene Enrichment and Functional Annotation Analysis
Given the lists of differentially expressed genes, we per-
formed an ontology term enrichment analysis using the
DAVID 2.1 tool to find gene functional classes specifi-
cally associated with those lists [22]. In such analysis,
the statistical association between being differentially
expressed and belonging to a given category is accessed
by the Fisher Exact test. The ontologies used were those
defined by the KEGG database of metabolic pathways
[23] and by the Gene Ontology Consortium [24]. The
probe-to-GO and the probe-to-KEGG mapping were
established based on the official annotation provided by
the manufacturer.
Real-time PCR quantification
Gene expression was quantified in hippocampi of rats
treated either with saline or pilocarpine, at different
times during the course of epileptogenesis (n = 5 per
experimental group). One microgram of total RNA was
used to synthesize cDNA by extension with oligo-dT
primers and 200 U of Superscript II Reverse Transcrip-
tase (Invitrogen Life Technologies). Quantitative
reverse-transcription polymerase chain reaction was per-
formed in a ABI 7500 Real-Time PCR System platform
(Applied Biosystems) by the Sybr-Green approach (Plati-
num SYBR Green qPCR SuperMix-UDG, Invitrogen Life
Technologies), using ROX as passive reference dye. All
samples were analyzed in the same plate, in a single
PCR run, and under identical conditions. Amplification
specificity was assessed by dissociation curve analysis.
Normalization of quantitative data was based on the
expression of the housekeeping gene glyceraldehyde-3-
phosphate dehydrogenase (GAPDH). Quantification was
based on 2-ΔΔCT method, using corresponding age-
matched control samples as calibrators. Amplification
reactions contained 2 μL of 1:10 diluted cDNA and 10
pmoles of each primer. Basic amplification cycle sug-
gested by the manufacturer was used, with an annealing
temperature of 60°C. Primer sequences were obtained
elsewhere: NESTIN FOR 5’ AGCAACTGGCACACCT
CAAG 3’, NESTIN REV 5’ GGTGTCTGCAAGC
GAAAGTTC 3’, GFAP FOR 5’ CTCAGTACGAGG
CAGTGGCC 3’, GFAP REV 5’ CGGGAAGCAACGT
CTGTGA 3’ [25], IGF1 FOR 5’ CACAGGCTATG
GCTCCAGCAT 3’, IGF1 REV 5’ TCTCCAGCCTCCT
CAGATCACA 3’ [26], CDK1 FOR 5’ CGGTTGA-
CATCTGGAGCATA 3’, CDK1 REV 5’ GCATTTTC
GAGAGCAAGTCC 3’, p18(INK4c) FOR 5’ ACCG
AACTGGTTTTGCTGTC 3’, p18(INK4c) REV 5’
GGGCAGGTTCCCTTCATTAT 3’ [27], TGFbeta1 FOR 5’
GAGAGCCCTGGATACCAACTACTG 3’, TGFbeta1 REV
5’ GTGTGTCCAGGCTCCAAATGTAG 3’ [28], GAPDH
FOR 5’ GAACCTGCCGTGGGTAGAG 3’, GAPDH REV
5’ AGGTCGGTGTGAACGGATTTG 3’ [29].
Statistical Analyses
Microarray data: statistically significant differences
among treatments were determined by the Student’s t
test and the Fisher Exact test. All conclusions are based
on at least 5% level of significance (P ≤ 0.05). Real-time
PCR data: analysis was performed with the GraphPad
Prism software, v.3.00 for Windows (San Diego, CA,
USA). Data were analyzed by Two-way ANOVA, Treat-
ment (2) × Time (3), with Bonferroni as post-hoc test,
since there was a normal distribution. Significance was
established at the P ≤ 0.05 level.
Results
Latent period of the pilocarpine model is marked by
dynamic changes at the molecular level
As extensively described by Turski et al., 1983 [19], a
single high dose of pilocarpine, a potent muscarinic cho-
linergic agonist originally isolated from the leaves of
South American shrubs, induced sequential behavioral
changes characteristic of sustained epileptic activity. Few
minutes after pilocarpine administration, the animals
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exhibited stereotypical oral and mastigatory movements,
hypokinesia, salivation, chewing, sniffing-head, tremor,
and partial or generalized limbic seizures that evolved to
SE. The mortality within the first 24 h of pilocarpine
administration was around 30%. Only those animals that
achieved SE and survived were included in the study
(n = 5 per experimental group). This acute phase was
followed by a latent period during which the animals
were initially comatose or unresponsive to their environ-
ment due to SE and progressively returned to normal
behavior, usually within three days post-SE. This period
is also described as a “silent” period due to the absence
o behavioral and electrographic evidences of seizures.
Spontaneous and recurrent seizures typically character-
ized by facial automatism, forelimb clonus, and rearing
followed by loss of postural control and generalized clo-
nic seizures lasting 25-35 sec. tend to occur later on,
being a hallmark of the chronic period of the pilocar-
pine model. Time to first spontaneous seizure ranged
from nine to 17 days. The latent period of the pilocar-
pine model of epilepsy is known to vary among animals
and our results are in agreement with the literature [16].
Although clinically silent, the period spanning SE and
the beginning of spontaneous seizure activity is critical
to evaluate changes that might be relevant to epilepto-
genesis. Therefore, a whole transcriptome analysis was
performed with the purpose of identifying genes differ-
entially expressed after pilocarpine-induced SE. The
starting total RNA used in the hybridizations was
extracted from hippocampi at different times during the
course of epileptogenesis. After a typical microarray-
based analysis (Figure 1), alterations in the expression of
almost 1,400 genes were detected, suggesting an intense
molecular activity during the latent to chronic phase
transition of the pilocarpine model. A total of 736, 328,
and 326 genes were found differentially expressed three
days post-SE (D3), seven days post-SE (D7), and after
the first spontaneous seizure (Chronic), respectively.
Noteworthy, the vast majority of these differentially
expressed genes (90%) had their expression up-regulated
after SE, while the remainder 10% corresponded to
hypo-expressed genes at the same time points analyzed
(D3 = 81, D7 = 19, Chronic = 31).
Pilocarpine-induced SE promotes constitutive changes in
gene expression
Among the 1,400 differentially expressed genes, of parti-
cular interest was the finding of a large group of 128
genes commonly over-expressed in D3, D7, and Chronic
groups, indicative of a stable gene up-regulation
throughout the latent to chronic phase transition of the
pilocarpine model. As depicted in the Venn diagram of
figure 1B, this amount of commonly over-expressed
genes is higher than the number of genes exclusively
up-regulated at each of the respective time points, with
the exception of D3. In contrast, among the down-regu-
lated genes, only two genes were found simultaneously
hypo-expressed at all time points analyzed and, to date,
no biological functions have been described for them.
Biological processes and signaling pathways associated
with epileptogenesis
When functionally classifying genes based on the Gene
Ontology Consortium terminology, a myriad of biological
processes could be related to the genes affected by SE.
Since the overall representation of genes and correspond-
ing annotated functions in the entire rat genome may
confer a bias in this type of functional classification and
because a single gene may belong to multiple functional
categories, one major challenge is to distinguish pro-
cesses and functions specifically associated with epilepto-
genesis from those found due to random chance.
Therefore, a statistical test was applied to circumvent this
issue and identify functional categories over-represented
among the genes regulated by SE in hippocampal cells.
Figure 2 summarizes the number of enriched genes,
their corresponding molecular functions, and respective
P-values for functional association. Such classification
strategy revealed that the subset of 128 genes commonly
up-regulated in D3, D7, and chronic groups were particu-
larly enriched in genes functioning in immune response
(including humoral defense mechanism and, more speci-
fically, complement and coagulation cascades), cell moti-
lity, apoptosis, and intracellular signaling cascades. The
differentially expressed genes and respective functional
categories are depicted in table 1. Regarding signaling
pathways, those corresponding to over- and hypo-
expressed genes during all experimental times studied
after SE are illustrated in table 2. From this later analysis,
it can be noticed that MAPK, Jak-STAT, Phosphatidyl
inositol, TGF-beta, and mTOR signaling pathways were
found regulated in pilocarpine-treated animals through-
out the epileptogenesis period evaluated.
Differential expression of the selected genes Nestin,
CDK1, p18(INK4c), TGF-b1, IGF-1 and GFAP was quan-
tified by real-time PCR in order to confirm the microar-
ray results. Similar results were found with both
techniques. Compared with the respective control
groups, Nestin, CDK1, and p18(INK4c) genes were
found significantly over-expressed only three days after
SE. On the other hand, TGF-b1, IGF-1, and GFAP genes
displayed significant variations in expression at all times
analyzed after SE (Figure 3).
Discussion
High throughput gene expression profiling data can be
correlated with a certain pathological condition, subtype
or phase of diseases. This genomic approach could
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facilitate the identification of molecular pathways and
physiological processes involved in the development of
complex multifactorial diseases such as epilepsy.
In animal models, differentially expressed genes have
been reported in response to SE induced by kainic acid
[11], pilocarpine [12,13], and by electric stimulation
(Kindling) [14,15]. Despite the large amount of data
already accumulated, a comparative meta-analysis is
difficult to carry out due to the different experimental
design and microarray platforms used in studies of
such kind. The amount of genes/transcripts
interrogated in most studies ranged from 1560 to
8000, corresponding to up to 25% of genes identified
in the rat genome. Furthermore, the interval after SE
in which gene expression has been evaluated varies
from as early as one day, when many genes functioning
in stress defense, inflammation, and cell death are
regulated in response to the excitotoxic insult, to as
late as 100 days post-SE, when gene expression reflects
a neural tissue suffering from multiple events of spon-
taneous seizures, with frequency and intensity of sei-
zures varying among testing animals.
Figure 1 Gene expression profiling during epileptogenesis. (A) Hierarchical clustering of hippocampal genes displaying greater than 2-fold
changes in expression following SE (P ≤ 0.05). Each row: relative expression of a single gene; each column: a biological sample; red: hyper-
expression; green: hypo-expression. Several genes exhibited a consistent hyper-expression throughout the time points analyzed (black bar
cluster) while others were mainly hyper-expressed at D3 (white bar cluster). (B) Venn diagram discriminating the amount of genes differentially
expressed three days post-SE (D3), seven days post-SE (D7), and immediately after the first spontaneous seizure (Chronic).
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Figure 2 Functional classification of genes differentially expressed during epileptogenesis. Fisher Exact test was applied to identify
functional categories over-represented among the genes regulated by SE in hippocampal cells, thereby ensuring statistical significance. D3 =
three days after SE; D7 = seven days after SE; Chronic = immediately after the first spontaneous seizure; Common = genes found differentially
expressed in all previous groups.
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Table 1 Genes commonly up-regulated throughout epileptogenesis, from the early events post-SE to the onset of
recurrent spontaneous seizures.
Accession No. Fold change Description
D3 D7 Chronic
Immune response
RN.72599 5,1 12,2 7,4 colony stimulating factor 1 receptor
RN.16195 3,7 4,0 3,2 caspase 11
RN.14655 9,6 5,6 4,1 integrin alpha l
RN.16643 4,8 4,2 3,1 fc receptor, igg, high affinity i
RN.2393 5,7 5,0 3,6 complement component 1, q subcomponent, gamma polypeptide
RN.6702 5,0 4,8 3,1 complement component 1, q subcomponent, beta polypeptide
RN.10089 4,7 4,2 3,8 cyclin-dependent kinase inhibitor 1a
RN.48861 5,2 4,8 3,6 vav 1 oncogene
RN.10748 2,9 3,9 5,5 cd4 antigen
RN.81052 2,7 4,5 4,5 complement component 4a
RN.5892 5,8 6,3 5,1 major histocompatibility complex, class ii, dm beta
RN.780 7,0 3,9 4,1 alpha-2-macroglobulin
RN.38575 3,2 3,8 3,5 neutrophil cytosolic factor 1
RN.100285 7,7 9,9 8,3 serine (or cysteine) peptidase inhibitor, clade g, member 1
RN.92197 4,7 6,5 5,9 linker for activation of t cells family, member 2
RN.3176 4,2 4,7 3,8 lymphocyte antigen 86 (predicted)
RN.101608 4,9 4,2 4,5 lymphocyte specific 1
RN.58420 3,1 2,6 2,7 similar to ikappab-zeta (predicted)
RN.16670 5,9 4,2 4,5 basic leucine zipper transcription factor, atf-like (predicted)
RN.98333 4,2 4,6 4,0 complement component 2
RN.42962 4,3 6,8 6,2 integrin beta 2
RN.105647 4,1 4,4 3,3 complement component 1, q subcomponent, alpha polypeptide
RN.37880 4,7 4,6 5,6 small inducible cytokine a4
RN.10330 6,7 4,8 5,9 cd8 antigen, beta chain
RN.10139 10,9 12,8 10,1 chemokine (c-c motif) ligand 3
RN.30043 4,8 5,7 4,9 tumor necrosis factor (ligand) superfamily, member 4
RN.3370 5,7 4,6 4,3 interferon gamma inducible protein 30
RN.90166 3,4 3,7 3,2 protein tyrosine phosphatase, receptor type, c
RN.33323 6,0 6,0 4,8 fc receptor, igg, low affinity iib
Humoral Defense Mechanism
RN.105647 4,1 4,4 3,3 complement component 1, q subcomponent, alpha polypeptide
RN.81052 2,7 4,5 4,5 complement component 4a
RN.72599 5,1 12,2 7,4 colony stimulating factor 1 receptor
RN.100285 7,7 9,9 8,3 serine (or cysteine) peptidase inhibitor, clade g, member 1
RN.2393 5,7 5,0 3,6 complement component 1, q subcomponent, gamma polypeptide
RN.10139 10,9 12,8 10,1 chemokine (c-c motif) ligand 3
RN.16670 5,9 4,2 4,5 basic leucine zipper transcription factor, atf-like (predicted)
RN.6702 5,0 4,8 3,1 complement component 1, q subcomponent, beta polypeptide
RN.42962 4,3 6,8 6,2 integrin beta 2
RN.33323 6,0 6,0 4,8 fc receptor, igg, low affinity iib
Complement and Coagulation Cascades
RN.81052 2,7 4,5 4,5 complement component 4a
RN.780 7,0 3,9 4,1 alpha-2-macroglobulin
RN.100285 7,7 9,9 8,3 serine (or cysteine) peptidase inhibitor, clade g, member 1
RN.9772 4,4 3,6 2,5 complement component 3a receptor 1
RN.6702 5,0 4,8 3,1 complement component 1, q subcomponent, beta polypeptide
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One distinct aspect of the present study is that the
experiments were designed to cover all possible changes in
the transcriptome of hippocampal cells, using a microarray
platform containing more than 34,000 oligonucleotide
probes representing transcripts from all annotated rat
genes to date. This whole-genome profiling was conducted
at three close time-points during the course of epilepto-
genesis, according to the pilocarpine model of epilepsy:
three and seven days post-SE, corresponding to early and
mid term of the latent phase, and immediately after the
first spontaneous seizure which corresponds to the onset
of the chronic phase. The major aim was to uncover genes
Table 1: Genes commonly up-regulated throughout epileptogenesis, from the early events post-SE to the onset of
recurrent spontaneous seizures. (Continued)
RN.98333 4,2 4,6 4,0 complement component 2
RN.21393 3,7 6,5 5,7 coagulation factor x
Cell Motility
RN.66513 5,8 7,2 5,8 arachidonate 12-lipoxygenase (predicted)
RN.6282 5,0 5,0 4,8 insulin-like growth factor 1
RN.2090 3,7 3,4 2,7 actin related protein 2/3 complex, subunit 1b
RN.14655 9,6 5,6 4,1 integrin alpha l
RN.95169 3,2 3,7 3,0 abi gene family, member 3
RN.101608 4,9 4,2 4,5 lymphocyte specific 1
RN.10139 10,9 12,8 10,1 chemokine (c-c motif) ligand 3
RN.49170 4,7 4,4 3,4 suppression of tumorigenicity 14
RN.42962 4,3 6,8 6,2 integrin beta 2
Apoptosis
RN.66513 5,8 7,2 5,8 arachidonate 12-lipoxygenase (predicted)
RN.6282 5,0 5,0 4,8 insulin-like growth factor 1
RN.16195 3,7 4,0 3,2 caspase 11
RN.16643 4,8 4,2 3,1 fc receptor, igg, high affinity i
RN.101608 4,9 4,2 4,5 lymphocyte specific 1
RN.3176 4,2 4,7 3,8 lymphocyte antigen 86 (predicted)
RN.7110 6,0 4,9 4,2 receptor-interacting serine-threonine kinase 3
RN.18985 4,0 5,0 3,3 protein tyrosine phosphatase, non-receptor type 6
RN.42962 4,3 6,8 6,2 integrin beta 2
RN.10089 4,7 4,2 3,8 cyclin-dependent kinase inhibitor 1a
RN.90166 3,4 3,7 3,2 protein tyrosine phosphatase, receptor type, c
RN.10250 4,6 2,7 3,2 growth arrest and dna-damage-inducible 45 alpha
Intracellular Signaling Cascade
RN.6282 5,0 5,0 4,8 insulin-like growth factor 1
RN.68084 6,3 4,3 7,7 b-cell leukemia/lymphoma 3 (predicted)
RN.780 7,0 3,9 4,1 alpha-2-macroglobulin
RN.35286 3,4 4,0 2,9 similar to ptpl1-associated rhogap 1 (predicted)
RN.138976 3,3 3,6 2,9 sh3-domain binding protein 2
RN.19450 19,4 25,9 18,5 adenylate cyclase 7
RN.38575 3,2 3,8 3,5 neutrophil cytosolic factor 1
RN.7110 6,0 4,9 4,2 receptor-interacting serine-threonine kinase 3
RN.18985 4,0 5,0 3,3 protein tyrosine phosphatase, non-receptor type 6
RN.11534 3,6 3,8 3,2 tyro protein tyrosine kinase binding protein
RN.10748 2,9 3,9 5,5 cd4 antigen
RN.48861 5,2 4,8 3,6 vav 1 oncogene
RN.40136 3,5 4,3 3,2 transforming growth factor, beta 1
*Only those genes and their corresponding functional classes found specifically enriched and significantly associated with epileptogenesis are shown (P-values ≤
0.001, according to the Fisher Exact Test for functional enrichment analysis). Expression data is given as fold change from control, at the three time points
analyzed after SE (D3 = three days after SE; D7 = seven days after SE; Chronic = immediately after the first spontaneous seizure).
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that might be involved in development of epilepsy and not
solely correlated with SE or seizures. However, given that
this strategy was applied to the whole hippocampus, infor-
mation regarding particular cell types and subregions
within the hippocampus in which abnormal gene expres-
sion occurs is not available and should be further
investigated.
Nonetheless, since pilocarpine-treated animals gener-
ally return to normal behavior within three days post-
SE, a molecular analysis at this time point should cap-
ture the early events leading to epilepsy with minimal
contamination by genes regulated in response to the
chemical treatment per se or as a consequence of tissue
damage. However, many of the genes found differen-
tially expressed three days post-SE were related to stress
response including participation in defense mechanisms
and wound healing. This result is in agreement with a
previous study by Becker et al., 2003 [12] reporting,
three days post-SE, a high proportion of up-regulated
genes in the dentate gyrus and CA1 regions of the hip-
pocampus being associated with cellular stress and
injury. However, under the same experimental condi-
tion, we also found a large group of genes functioning
in cell proliferation and migration, supporting that neu-
rogenesis is triggered early in latent phase.
In agreement with this assumption, quantitative real-time
PCR analysis of cell cycle genes confirmed hyper-expression
of CDK1, a gene regulating the G1 to S and G2 to M transi-
tion of the cell cycle, and Nestin, a marker of neural stem
cells and neural progenitor cells. However, expression of
the cell cycle inhibitor p18(INK4c) was paradoxically
enhanced after SE and coincide with the peak of CDK1 and
Nestin expression at day three post-SE. No significant dif-
ferences in the expression of these genes were observed
seven days post-SE or after the first spontaneous seizure.
Recent studies have reported that members of the cyclin
dependent kinase family are up-regulated during epilepto-
genesis [30]. However, the hyper-expression of the cell
cycle inhibitor p18(INK4c) found after SE had not been pre-
viously reported. This finding suggests that the proliferative
stage of neurogenesis in the hippocampus of adult rats may
be inhibited by such activation of p18(INK4c).
Moreover, when examining gene expression profiles in
animals that had experienced only one spontaneous sei-
zure after SE, a time by when all essential changes for
the installation of epilepsy are expected to be manifested
in the central nervous system, there was a primarily up-
regulation of genes functioning in protein expression
and post-translational processing, including many tran-
scription factors, kinases and other transferases, along
with genes regulating cell differentiation such as FOXD3
and RUNX1. These two genes are of particular interest
since they encode transcription factors involved in
maintenance of embryonic stem cell pluripotency and
proliferation of neural progenitors, respectively [31,32].
Since commitment of stem cells to the neuronal lineage
is associated with repression of FOXD3 expression [33],
it is reasonable to assume that its hyper-expression
could be implicated in inhibition of neuroprogenitor dif-
ferentiation. This observation is in line with a marked
repression of genes regulating cell fate, development,
and morphogenesis such as LDB2, BMP3, and MAP2K1
detected in pilocarpine-treated animals at the beginning
of the chronic phase.
Altogether, these findings suggest that neurogenesis
may be impaired by different mechanisms throughout
the period corresponding to the latent to chronic phase
transition of the pilocarpine model. Indeed, anomalous
neurogenesis has been implicated in the development of
epilepsy [34,35]. Prolonged seizures are known to
Table 2 Regulatory signal transduction pathways and corresponding gene members found differentially expressed
during epileptogenesis.
Signaling
Pathway
D3 vs. CTRL D7 vs. CTRL CHRONIC vs. CTRL D3, D7 and CHRONIC vs. CTRL
Up-regulated Down-
regulated
Up-
regulated
Down-
regulated
Up-regulated Down-
regulated
Up-regulated Down-
regulated
MAPK Tgfbr1, Acvr1c Prkcc Tgfb1 - P38 Mapk, Fgf7,
Rasa2
Map2k1 Cacna1g, Casp4,
Gadd45a
-
Wnt Plcb2 Prkcc - - - - - -
Notch - Hes5 - - - - - -
TGF-beta Tgfbr1, Tgfb1,
Acvr1c
- Tgfb1 - Tgfb1 - Tgfb1 -
Jak-STAT Stat3, Jak3 - Pik3r1,
Ifngr1
- Pik3r3 - Csf2rb1 -
Calcium Plcb2 Prkcc, Cckbr - - - - Cacna1g -
Phosphatidyl
Inositol
Plcb2 Prkcc Pik3r1 - Pik3r3 - Pik3c2b -
mTOR Igf1 Igf1 Igf1 Igf1
*D3 = three days post-SE; D7 = seven days post-SE; Chronic = immediately after the first spontaneous seizure; CTRL = saline-treated, time-matched control.
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Figure 3 Validation of microarray data by quantitative real-time PCR. Relative gene expression in both control (CTRL) and pilocarpine (PILO)
groups. Labels: (■) 3 days post-SE, (○) 7 days post-SE, and (▲) right after the first spontaneous seizure (Chronic). *P ≤ 0.05; **P ≤ 0.01; ***P ≤
0.001.
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stimulate neurogenesis in the dentate gyrus, although
new born neurons display abnormal apical dendritic
morphology, and the ensuing plasticity of the hippocam-
pal network can lead to aberrant neuronal connections
associated with epileptogenesis [36,37]. Furthermore,
fate decision of proliferating neuronal progenitors in the
hippocampus has been reported to be impaired after
intra-hippocampal injection of kainic acid, favoring
astrogliosis [38]. Prolonged seizures have also been
reported to induce aberrant migration of newborn
neurons to the hilus and inner molecular layer of the
dentate gyrus, contributing to the formation of a hyper-
excitable circuitry [39,35].
Another intriguing result that emerged from the com-
parative analysis of genes differentially expressed at each
of the three time points post-SE was the identification of
a group of 128 genes continually up-regulated through-
out the course of epileptogenesis. This finding was some-
what unexpected since cellular activity in response to its
microenvironment stimuli is dynamically regulated
through transient and specific changes in gene expres-
sion. One possible interpretation is that the SE may cause
stable alterations in the microenvironment, exposing the
remaining cells to nonstandard cues. Alternatively, the
nature of cell population within the hippocampus may be
shifted after SE, accommodating a greater proportion of
activated microglial cells and other cells of abnormal
phenotype expressing a different repertoire of genes.
Consistent with the literature, a functional classifica-
tion of these 128 up-regulated genes indicated that most
of them are involved in signaling cascades, extracellular
matrix remodeling and cell motility, apoptosis, and
immune response, which are processes known to be
associated with epileptic seizures. In particular, the high
proportion of immune response genes and the activation
of genes from the p38 MAPK signaling pathway, some
of which confirmed by real-time PCR, are in agreement
with a chronic activation of microglial cells [40].
Furthermore, up-regulation of proinflammatory genes in
both cortex and hippocampus of patients with TLE have
been recently reported [41].
Based on experimental and clinical evidences, inflam-
mation and neurogenesis seem to be common factors
contributing to the development of epilepsy. Since
microglia activation suppresses hippocampal neurogen-
esis in adult brain [42], modulation of genes and path-
ways connecting both processes should have an impact
on epileptogenesis. Whether some of the genes hereby
found regulated during epileptogenesis should fall into
this category of relevance remains to be elucidated.
Interestingly, the steady up-regulation of the inflamma-
tory peptide TGF-beta1 detected throughout epilepto-
genesis might be one of such factors contributing to an
anomalous neurogenesis. This hypothesis is reinforced
by a recent report by Cacheaux et al., 2009 [43], describ-
ing involvement of the TGF-beta pathway in the devel-
opment of epilepsy caused by brain injury.
Conclusions
In summary, our whole-genome screening indicate
remarkable changes in the rat transcriptome along the
latent to chronic phase transition of the pilocarpine
model of epilepsy. Over a thousand genes had their
expression altered after SE, most of which displaying an
up-regulation, and their functional classification provide
a molecular portrait of the epileptogenic process. There
was a consistent regulation of genes functioning in neu-
rogenesis, apoptosis, immune response, and intracellular
signal transduction, some of which with parallel expres-
sion patterns in patients with epilepsy, strengthening the
link between these processes and development of TLE.
Most differentially expressed genes identified are novel
and could now be further tested to provide experimental
and clinical evidences of functional relevance to epilep-
togenesis. In particular, genes mediating inflammation
and neurogenesis such as those from the TGF-beta sig-
naling pathway are of particular interest and shall be
pursued as targets for molecular therapy.
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